Simris Group advances two amanitin-based ADC programs toward the clinic
Simris Group AB confirms its strategy to develop amanitin-derived novel payloads to overcome treatment resistance in liquid and solid tumors. With strengthened specialist leadership, it will advance two proprietary Antibody-Drug Conjugate programs toward clinical development.
Simris Group AB (publ) said it is pursuing amanitin-derived novel payloads aimed at overcoming treatment resistance in both liquid and solid tumors. With strengthened specialist leadership, the company said it will focus on advancing two proprietary Antibody-Drug Conjugate programs toward the clinic.